What Is Retatrutide?

1. What Is Retatrutide?

Retatrutide is an investigational molecule being developed by Lilly. Lilly’s own retatrutide FAQ describes it as a once-weekly triple hormone receptor agonist and says it activates the body’s receptors for glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon.

That receptor list is the core fact. Retatrutide is not simply “another GLP-1” in the same way semaglutide is a GLP-1 receptor agonist. It is also different from tirzepatide, which current U.S. labels describe as a dual GIP and GLP-1 receptor agonist. Retatrutide adds glucagon receptor activity to the GIP and GLP-1 receptor conversation.

The clean way to read the name is:

For broader receptor-language background, see GLP-1 vs GLP-2 vs GLP-3 and What Is a GLP-1?.

2. Why Is Retatrutide Called a Triple Agonist?

Retatrutide is called a triple agonist because Lilly describes it as one molecule that activates three receptor pathways: GIP, GLP-1, and glucagon. That wording is more precise than calling it only a GLP-1 medication, even though GLP-1 is the term most people recognize from semaglutide and tirzepatide headlines.

The public vocabulary gets messy because “GLP-1” has become a cultural umbrella. It may refer to a natural hormone, a receptor pathway, a medicine category, or an informal group of injectable metabolic drugs. Retatrutide sits near that conversation but does not fit neatly inside the older shorthand.

The receptor stack looks like this:

This is naming context, not a ranking. A mechanism description does not say which product is appropriate, what results someone should expect, or whether a research molecule will become an approved drug. For related molecule explainers, see What Is Semaglutide? and What Is Tirzepatide?.

3. Is Retatrutide FDA-Approved?

No. Retatrutide is not FDA-approved as of May 2026. Lilly states that retatrutide is investigational, has not been reviewed or approved by any regulatory agency, and is legally available only to participants in Lilly clinical trials.

That status is not a small footnote. It changes the scope of every claim. A Phase 2 article, a Phase 3 press release, and a ClinicalTrials.gov record can describe research progress, but they do not create an approved label, a public supply, or prescribing instructions.

This page keeps that investigational status separate from access claims, compounded-product claims, products sold online as retatrutide, and personal use questions. Lilly’s public page also warns about fake medicines in the retatrutide discussion.

For an educational resource, the appropriate boundary is simple:

• Retatrutide is a research molecule.
• Lilly is studying it in Phase 3 programs.
• It is not an approved FDA-labeled medication.
• Research findings are not personal medical instructions.

4. What Did the Phase 2 NEJM Study Show?

The 2023 New England Journal of Medicine Phase 2 article studied retatrutide in adults with obesity or overweight, without type 2 diabetes. Lilly’s 2023 summary of those data said retatrutide reached up to 17.5% mean weight reduction at 24 weeks and up to 24.2% at 48 weeks in the highest-dose group under the efficacy estimand.

Those results helped explain why retatrutide became highly discussed before approval. The trial suggested substantial weight reduction in the studied population, and Lilly said weight had not plateaued by the end of the 48-week treatment period. The study also reported gastrointestinal adverse events as the most common side effects, generally during dose escalation.

The important restraint is that Phase 2 data are not a product label. A mid-stage trial helps researchers decide whether and how to move into larger Phase 3 trials. It does not answer whether retatrutide is safe and effective for broad public use, whether future results will match earlier results, or whether a regulatory agency will approve it.

Phase 2 was the signal. Phase 3 is the larger test.

5. What Did TRIUMPH-4 Report?

Lilly’s December 11, 2025 TRIUMPH-4 press release described a Phase 3 trial in adults with obesity or overweight and knee osteoarthritis, without diabetes. Lilly reported that participants in the highest retatrutide arm lost an average of 28.7% of body weight, or 71.2 pounds, at 68 weeks.

That headline is striking, but the population matters. TRIUMPH-4 was not a general public weight-loss survey. ClinicalTrials.gov describes NCT05931367 as a randomized, double-blind, placebo-controlled Phase 3 study of weekly retatrutide in participants with obesity or overweight and osteoarthritis of the knee. The trial asked research questions about both weight and knee osteoarthritis outcomes in that defined study population.

The safest way to discuss TRIUMPH-4 is therefore narrow and sourced:

The trial result can be important without being turned into a promise. The number does not establish the same response, the same eligibility, or public access to retatrutide.

6. What Is TRANSCEND-T2D-1?

TRANSCEND-T2D-1 is Lilly’s Phase 3 type 2 diabetes topline readout for retatrutide, announced on March 19, 2026. Lilly described it as a 40-week randomized, double-blind, placebo-controlled trial in adults with type 2 diabetes and inadequate glycemic control with diet and exercise alone.

In that press release, Lilly said retatrutide met the primary endpoint and key secondary endpoints versus placebo. The company reported average A1C reductions up to 2.0% across retatrutide arms and average weight loss up to 36.6 pounds, or 16.8%, at 40 weeks using the efficacy estimand.

This context matters because retatrutide is not being studied only as an obesity molecule. Lilly says it is evaluating retatrutide across several Phase 3 clinical trials, including obesity and overweight with weight-related medical problems, type 2 diabetes, knee osteoarthritis pain, obstructive sleep apnea, chronic low back pain, cardiovascular and renal outcomes, and metabolic dysfunction-associated steatotic liver disease.

That pipeline breadth should still be read carefully. Topline press releases are not the same as peer-reviewed full trial publications, and neither is the same as an approved indication.

7. Why “GLP-3” Is an Awkward Nickname

“GLP-3” is an informal nickname that tries to compress retatrutide into a memorable phrase. Lilly’s retatrutide FAQ calls GLP-3 scientifically inaccurate and says “triple agonist” is a more suitable term because it reflects the three receptor targets.

The nickname is understandable. People already know GLP-1, tirzepatide is often explained as dual GIP/GLP-1, and retatrutide adds a third receptor pathway. “GLP-3” sounds like a sequel. But it is not a formal receptor category, an approved class name, or a label term.

For clear writing, use:

• Retatrutide when naming the molecule.
• Investigational when describing regulatory status.
• Triple GIP/GLP-1/glucagon receptor agonist when describing the mechanism shorthand.
• “GLP-3” only when explaining informal public language.

That keeps the page understandable without letting a catchy nickname replace the scientific wording. Because retatrutide remains investigational, research names and trial outcomes are source context rather than instructions or product availability.

8. Sources

9. What Is Retatrutide FAQ

• What is retatrutide in simple terms?

  Retatrutide is Lilly’s investigational triple hormone receptor agonist. It is designed as a single molecule that activates receptors for GIP, GLP-1, and glucagon. It is still investigational and is not FDA-approved as of May 2026.

• Is retatrutide FDA-approved?

  No. Lilly states that retatrutide is investigational, not currently approved by the FDA, and legally available only to participants in Lilly clinical trials. This page does not discuss how to obtain or use it.

• Why do people call retatrutide a triple agonist or GLP-3?

  Triple agonist is the more accurate shorthand because retatrutide targets three receptor pathways: GIP, GLP-1, and glucagon. GLP-3 is an informal media nickname, not an official scientific drug class.

• What did the TRIUMPH-4 press release report?

  Lilly’s December 2025 TRIUMPH-4 press release described a Phase 3 trial in adults with obesity or overweight and knee osteoarthritis. Lilly reported average weight loss up to 28.7%, or 71.2 pounds, at 68 weeks in the highest retatrutide arm, while noting retatrutide remains investigational.